336 related articles for article (PubMed ID: 33289297)
21. Sotagliflozin: First Global Approval.
Markham A; Keam SJ
Drugs; 2019 Jun; 79(9):1023-1029. PubMed ID: 31172412
[TBL] [Abstract][Full Text] [Related]
22. Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.
Araki E; Mathieu C; Shiraiwa T; Maeda H; Ikeda H; Thoren F; Arya N; Asano M; Iqbal N
Diabetes Obes Metab; 2021 Jul; 23(7):1496-1504. PubMed ID: 33620762
[TBL] [Abstract][Full Text] [Related]
23. Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Peters AL; McGuire DK; Danne T; Kushner JA; Rodbard HW; Dhatariya K; Sawhney S; Banks P; Jiang W; Davies MJ; Lapuerta P
Diabetes Care; 2020 Nov; 43(11):2713-2720. PubMed ID: 32928957
[TBL] [Abstract][Full Text] [Related]
24. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
Patel K; Carbone A
Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
[No Abstract] [Full Text] [Related]
25. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Danne T; Biester T; Kordonouri O
Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
[TBL] [Abstract][Full Text] [Related]
26. Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
Powell DR; Zambrowicz B; Morrow L; Beysen C; Hompesch M; Turner S; Hellerstein M; Banks P; Strumph P; Lapuerta P
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1235-49. PubMed ID: 31837264
[TBL] [Abstract][Full Text] [Related]
27. Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study.
Posch MG; Walther N; Ferrannini E; Powell DR; Banks P; Wason S; Dahmen R
Diabetes Care; 2022 Sep; 45(9):2118-2126. PubMed ID: 35817022
[TBL] [Abstract][Full Text] [Related]
28. Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes.
Stougaard EB; Rossing P; Vistisen D; Banks P; Girard M; Davies MJ; Persson F
Diabetes Obes Metab; 2023 Jul; 25(7):1874-1882. PubMed ID: 36872068
[TBL] [Abstract][Full Text] [Related]
29. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
Groop PH; Dandona P; Phillip M; Gillard P; Edelman S; Jendle J; Xu J; Scheerer MF; Thoren F; Iqbal N; Repetto E; Mathieu C
Lancet Diabetes Endocrinol; 2020 Oct; 8(10):845-854. PubMed ID: 32946821
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
31. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
32. Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.
Elian V; Popovici V; Karampelas O; Pircalabioru GG; Radulian G; Musat M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396657
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.
Cherney DZI; Ferrannini E; Umpierrez GE; Peters AL; Rosenstock J; Powell DR; Davies MJ; Banks P; Agarwal R
Diabetes Obes Metab; 2023 Jun; 25(6):1646-1657. PubMed ID: 36782093
[TBL] [Abstract][Full Text] [Related]
34. An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes.
Chatzopoulos G; Tziomalos K
Expert Opin Pharmacother; 2020 Oct; 21(15):1799-1803. PubMed ID: 33108240
[TBL] [Abstract][Full Text] [Related]
35. Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis.
Avgerinos I; Karagiannis T; Kakotrichi P; Michailidis T; Liakos A; Matthews DR; Tsapas A; Bekiari E
Diabetes Obes Metab; 2022 Jan; 24(1):106-114. PubMed ID: 34545668
[TBL] [Abstract][Full Text] [Related]
36. Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review.
Hropot T; Battelino T; Dovc K
Horm Res Paediatr; 2023; 96(6):620-630. PubMed ID: 36279850
[TBL] [Abstract][Full Text] [Related]
37. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium-glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020).
Dashora U; Patel DC; Gregory R; Winocour P; Dhatariya K; Rowles S; Macklin A; Rayman G; Nagi D;
Diabet Med; 2021 Feb; 38(2):e14458. PubMed ID: 33179277
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
Lingvay I; Greenberg M; Gallo S; Shi H; Liu J; Gantz I
Diabetes Obes Metab; 2021 Jul; 23(7):1640-1651. PubMed ID: 33769675
[TBL] [Abstract][Full Text] [Related]
39. Dapagliflozin: A Review in Type 1 Diabetes.
Paik J; Blair HA
Drugs; 2019 Nov; 79(17):1877-1884. PubMed ID: 31664708
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials.
Yang Y; Pan H; Wang B; Chen S; Zhu H
Chin Med Sci J; 2017 Apr; 32(1):22-7. PubMed ID: 28399981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
